Akebia Therapeutics - AKBA Book Value per Share

Symbol and logo of brand Akebia Therapeutics (AKBA)

The price evolution chart on GURU.Markets helps assess the risks of Akebia Therapeutics (AKBA), whose operating model relies on external manufacturing and testing contractors, making the 0.09 metric sensitive to logistics. The company delegates formula development to third-party sites to focus on R&D. Proprietary drug patents and regulatory requirements ensure a high barrier to entry, creating a sustainable competitive advantage.

AKBA Akebia Therapeutics Inc Share Book Value (07/04/2022 - 11/01/2026)

Summary analytical data breakdowns for akebia.com (AKBA)

- stock price and consensus target price:
Stock Price Akebia|AKBA - Price Target Chart
- issuer market value details:
Market Capitalization Akebia Therapeutics, Inc.|AKBA - Enterprise Value
- business book valuation details:
Net Assets per Single Share Akebia Therapeutics|AKBA - Net Asset Value|Market Capitalization to Book Value Ratio akebia.com|AKBA - Aggregate Asset Value
- debt level and financial liquidity data:
Total Debt to Capital Akebia Therapeutics|AKBA - Long-Term Debt to Capital|Short-Term Debt to Equity Akebia Therapeutics, Inc.|AKBA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Akebia Therapeutics, Inc.|AKBA - Company Long-Term Liabilities|Company Short-Term Debts Akebia Therapeutics|Quick Liquidity Indicator akebia.com
- earnings and multiples data:
AKBA - Final Profit
General company analysis:AKBA - Akebia
Manufactured products of Akebia Therapeutics, Inc.

Assess the financial stability of Akebia Therapeutics (AKBA) through the lens of its equity. The book value per share reflects the difference between all company assets and liabilities, divided by the number of outstanding securities. By analyzing book value per share data, an investor determines the intrinsic value of the business. Under an asset-light model and the use of contract manufacturing, this indicator focuses on the value of intellectual property. Growth in this metric confirms the capitalization of R&D developments without excessive expenditures on manufacturing plants.

Competitor analysis

Retrophin - Book Value per Share|ARDX: Net Assets per Single Share|PROK: Book Value per Share|caratherapeutics.com (TVRD) - Book Value per Share|Net Assets per Single Share DiaMedica Therapeutics Inc.|Unicycive Therapeutics Inc. - Share Book Value|Book Value per Share RMTI|CVKD (Cadrenal Therapeutics Inc) - Accounting Value of a Share|Book Value per Share CDT (Conduit Pharmaceuticals)|Book Value per Share Calliditas Therapeutics, Inc. CALT|RNLX - Net Assets per Single Share|Accounting Value of a Share ZVSA (ZyVersa Therapeutics)